Imlygic and Sitavig
Determining the interaction of Imlygic and Sitavig and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Acyclovir may reduce the effectiveness of talimogene laherparepvec in treating your condition. Talk to your doctor if you have any questions or concerns. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:MONITOR: Antiherpetic antiviral agents may interfere with the therapeutic effects of talimogene laherparepvec, which is a live, attenuated herpes simplex virus.
MANAGEMENT: Because talimogene laherparepvec is sensitive to antiviral agents such as acyclovir, the risks and benefits of talimogene laherparepvec should be considered before administering antiviral agents to manage herpetic infection.
- "Product Information. Imlygic (talimogene laherparepvec)." Amgen USA, Thousand Oaks, CA.
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Imlygic-Sivextro
- Imlygic-Sivextro (Tedizolid Injection)
- Imlygic-Sivextro (Tedizolid Tablets)
- Imlygic-Sivextro Intravenous
- Imlygic-Sivextro tablet, film coated; lyophilized powder for injection
- Imlygic-Skelaxin
- Sitavig-Immune Globulin (Human)-hipp (Subcutaneous)
- Sitavig-Immune Globulin (Human)-ifas (IV)
- Sitavig-Immune Globulin (Human)-klhw (Subcutaneous)
- Sitavig-Immune globulin (intramuscular) IGIM
- Sitavig-Immune globulin (intravenous) IGIV
- Sitavig-Immune globulin and hyaluronidase Subcutaneous